Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sargramostim inhalation - Nobel Pharma

Next Previous
Drug Profile

Sargramostim inhalation - Nobel Pharma

Alternative Names: Sargramostim-inhalation; sargramostiminhalation

Latest Information Update: 16 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nobelpharma
  • Class Adjuvants; Anti-infectives; Antidementias; Antineoplastics; Antiparkinsonians; Antivirals; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Radioprotectives; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III COVID-19 respiratory infection

Most Recent Events

  • 16 Oct 2023 Sargramostim is still in phase II/III trial for COVID-19 respiratory infection (Adjunctive treatment) in Japan (Inhalation) (NCT04642950)
  • 17 Dec 2020 Phase-II/III clinical trials in COVID-19 respiratory infection (Adjunctive treatment) in Japan (Inhalation)
  • 24 Nov 2020 Preclinical trials in COVID-19 respiratory infection in Japan (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top